Edgewise Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Edgewise Therapeutics, Inc. (EWTX) reported Increase (Decrease) in Accounts Payable of $2.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Edgewise Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $781.00K.
- Edgewise Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.45M, a 49.41% decline year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$303.00K, a 429.35% decline year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$2.13M.
- Edgewise Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $272.00K, a 84.34% decline from fiscal 2024.
- Edgewise Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.74M.
- Edgewise Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$92.00K, a 295.74% decline from fiscal 2022.
- Edgewise Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $47.00K, a 98.23% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $781.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.23M 10-Q · filed 2026-08-06 | $1.92M derived: sum of 3 quarters · filed 2026-08-06 | -$208.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.45M 10-Q · filed 2026-05-07 | $1.14M derived: sum of 2 quarters · filed 2026-05-07 | -$989.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$303.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.44M derived: sum of 2 quarters · filed 2026-02-26 | -$2.59M derived: sum of 3 quarters · filed 2026-08-06 | $272.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.28M derived: sum of 2 quarters · filed 2026-08-06 | $575.00K 10-Q · filed 2025-11-06 | $667.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.71M 10-Q · filed 2026-08-06 | $2.80M derived: sum of 3 quarters · filed 2026-08-06 | $1.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.86M 10-Q · filed 2026-05-07 | $2.95M derived: sum of 2 quarters · filed 2026-05-07 | $1.92M derived: sum of 3 quarters · filed 2026-05-07 | $3.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$936.00K derived: sum of 2 quarters · filed 2026-02-26 | $957.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.74M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $865.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.65M 10-Q · filed 2025-11-06 | $263.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.67M 10-Q · filed 2025-08-07 | $1.29M derived: sum of 3 quarters · filed 2026-02-26 | $3.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $780.00K 10-Q · filed 2025-05-08 | -$602.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.16M derived: sum of 3 quarters · filed 2026-02-26 | $848.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $380.00K derived: sum of 2 quarters · filed 2026-02-26 | $68.00K derived: sum of 3 quarters · filed 2026-02-26 | -$92.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.45M derived: sum of 2 quarters · filed 2024-11-07 | $1.29M 10-Q · filed 2024-11-07 | $1.87M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$312.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$472.00K 10-Q · filed 2024-08-08 | $104.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.04M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$160.00K 10-Q · filed 2024-05-09 | $416.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.35M derived: sum of 3 quarters · filed 2024-05-09 | -$1.30M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $576.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.51M derived: sum of 2 quarters · filed 2024-02-22 | -$1.14M derived: sum of 3 quarters · filed 2024-02-22 | $47.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $938.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.72M derived: sum of 2 quarters · filed 2023-11-09 | -$529.00K 10-Q · filed 2023-11-09 | $1.02M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.47M 10-Q · filed 2023-08-10 | $84.00K derived: sum of 3 quarters · filed 2023-08-10 | -$440.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.19M 10-Q · filed 2023-05-11 | $2.74M derived: sum of 2 quarters · filed 2023-05-11 | $2.21M derived: sum of 3 quarters · filed 2023-05-11 | $3.90M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.03M derived: sum of 2 quarters · filed 2023-02-23 | $2.72M derived: sum of 3 quarters · filed 2023-02-23 | $2.65M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$524.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.17M derived: sum of 2 quarters · filed 2022-11-03 | $1.10M 10-Q · filed 2022-11-03 | $1.24M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.63M 10-Q · filed 2022-08-04 | $1.76M derived: sum of 3 quarters · filed 2022-08-04 | $1.97M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$63.00K 10-Q · filed 2022-05-11 | $74.00K derived: sum of 2 quarters · filed 2022-05-11 | $279.00K derived: sum of 3 quarters · filed 2022-05-11 | $0.00 derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $342.00K derived: sum of 2 quarters · filed 2022-02-24 | $63.00K derived: sum of 3 quarters · filed 2022-02-24 | $521.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $205.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$74.00K derived: sum of 2 quarters · filed 2021-11-10 | $384.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $179.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $458.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |